Allergan Performs Better Than Expected, But Still Conducting Strategic Review

Financials are holding up well despite generics launching against multiple Allergan products, but with stock price falling the company is conducting a strategic review to make sure it isn't missing out on any alternative business strategies that could boost the enterprise's value.

Man with report

Allergan PLC Chairman, President and CEO Brent Saunders made it clear that he thinks the company is on the right track with financial performance that backs up his view, but a strategic review is ongoing anyway to show investors that Allergan is "doing something" that could boost its stock value.

The company's first quarter earnings conference call on April 30 was its first big opportunity to discuss a strategic review...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business